Our results confirmed that UBE2CP3 was overexpressed in most types of tumors, including breast cancer (BRCA), colon cancer (COAD), esophageal cancer (ESCA), head and neck squamous cell carcinoma (HNSC), rectum adenocarcinoma (READ), and stomach cancer (STAD), suggesting UBE2CP3 may function important roles in tumor progression (Fig. 2A). This evidence concerns the gene UBE2CP3 and esophageal cancer.